论文部分内容阅读
在美国和西方国家中 ,冠心病 (ＣＨＤ)是绝经后妇女死亡的主要原因。一些研究表明 ,单用雌激素补充疗法或加孕激素治疗的绝经后妇女 ,其ＣＨＤ危险性较未治疗者约减少 30 %。雷洛昔芬 (ｒａｌｏｘｉｆｅｎｅ)多重结果评估 (ＭＯＲＥ)研究是一项确定该药对有骨质疏松的绝经后 77
In the United States and Western countries, coronary heart disease (CHD) is the leading cause of postmenopausal women’s death. Some studies have shown that menopausal women treated with estrogen replacement therapy or progestin alone have a 30% lower risk of CHD than those who have not. Raloxifene (raloxifene) multiple outcome evaluation (MORE) study is a confirmed that the drug has osteoporosis after menopause 77